Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: J Allergy Clin Immunol. 2021 Aug 4;149(2):747–757. doi: 10.1016/j.jaci.2021.06.028

Table IV.

Causes of death.

Day of life Days after CTT Causes of Death (N = 28)*

Related to Infection (n = 13)

471 24 Progression of underlying PIV3 pneumonia
398 44 Sepsis
586 89 Death secondary to disseminated Candida infection
247 103 Progressive cerebral atrophy due to CMV
181 130 Sepsis
199 130 Sepsis
350 149 Respiratory failure from disseminated mycobacterial infection
264 160 Respiratory failure due to respiratory syncytial virus
416 234 Respiratory failure secondary to sepsis from Candida tropicalis and C parapsilosis
382 252 Respiratory complications from CMV infection
804 263 Multiorgan system failure as seen in severe septic shock
856 339 Methicillin resistant Staphylococcus aureus bacteremia
824 375 Presumed sepsis

All Except for Infection (n = 15)

107 0 Hemorrhage with Nissen fundoplication surgery
172 45 Respiratory failure
162 66 Severe bilateral intraventricular hemorrhage
268 82 Hypoxia
537 108 Cardiorespiratory arrest related to anasarca
5879 116 Progression of EBV lymphoma resulting in intracranial bleeding and death
510 128 Large right parietal hemorrhage
256 137 Respiratory failure
667 229 Respiratory failure
392 289 Respiratory failure
982 480 Sudden catastrophic intracranial hemorrhage
1622 950 Not reported
1713 1617 Cardiopulmonary arrest
2918 2769 Respiratory failure
3311 3116 Respiratory failure

CMV, cytomegalovirus; EBV, Epstein-Barr virus; PIV3, parainfluenza virus type 3

*

Includes 2 deaths in patients who withdrew from the study prior to having a reportable adverse event.